Who
Eiry Roberts
Director
Company insider
Files Form 4 as: Director, Bausch Health Companies; Director, Amicus Therapeutics; Chief Medical Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 123
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $21.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 8 Jan 2018
- Last trade
- 22 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus TherapeuticsBiotechnology | SEC FORM 4 Code D | $1.1M76,275 at $14.50 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,625 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,423 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,625 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —45,423 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,474 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,467 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —74,872 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,474 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,467 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —74,872 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeutics | SEC FORM 4 Code D | $1.1M76,275 at $14.50 | filing |
| 5 Jun 2025filed 6 Jun 2025 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code A | —74,872 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | Amicus Therapeutics | SEC FORM 4 Code A | —20,414 at $0.00 | filing |
| 14 Feb 2025filed 14 Feb 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $58K500 at $115.04 | filing |
| 13 Feb 2025filed 14 Feb 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,113 at $0.00 | filing |
| 13 Feb 2025filed 14 Feb 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,120 at $0.00 | filing |
| 13 Feb 2025filed 14 Feb 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,372 at $0.00 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Eiry Roberts; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.